Tương Tác Dược Dược Lý Giữa Thuốc Thảo Dược và Thuốc: Cơ Chế và Ý Nghĩa Lâm Sàng
Tóm tắt
Hiệu quả điều trị của một loại thuốc hoặc các tác dụng không mong muốn không dự đoán được của nó có thể phụ thuộc vào việc sử dụng đồng thời một loại cây thuốc. Cụ thể, các thành phần trong chiết xuất cây thuốc có thể ảnh hưởng đến khả năng sinh khả dụng, chuyển hóa và thời gian bán hủy của thuốc, dẫn đến độc tính của thuốc hoặc không đạt được phản ứng điều trị. Bài tổng quan này tập trung vào các nghiên cứu lâm sàng nhằm nâng cao nhận thức về khả năng của những thuốc thảo dược được chọn lựa để ảnh hưởng đến dược động học của các thuốc cùng được sử dụng. Hơn nữa, các nghiên cứu in vitro có thể hữu ích để dự đoán các tương tác giữa thuốc thảo dược và thuốc. Cụ thể, chúng giúp làm sáng tỏ các mục tiêu tế bào (protein chuyển hóa hoặc protein vận chuyển) và cơ chế (kích thích hoặc ức chế) mà một thành phần đơn lẻ của thuốc thảo dược tác động. Các tác giả làm nổi bật những khó khăn trong việc dự đoán các tương tác thuốc thảo dược từ dữ liệu in vitro, trong trường hợp nồng độ cao của các chiết xuất hoặc các thành phần của chúng được sử dụng và dược động học không được xem xét. Ngoài ra, cũng thảo luận về khó khăn trong việc so sánh kết quả từ các nghiên cứu trên người khi có các loại chiết xuất thảo dược khác nhau được sử dụng. Các thuốc thảo dược được thảo luận là trong số những sản phẩm bán chạy nhất và được ghi nhận trong phần "Thuốc Thảo Dược Để Sử Dụng Ở Người" của Cơ Quan Dược Phẩm Châu Âu (EMA).
Từ khóa
#Tương tác thuốc thảo dược #dược động học #hiệu quả điều trị #thuốc thảo dược #nghiên cứu lâm sàng #nghiên cứu in vitro.Tài liệu tham khảo
Cassileth, 2009, The Public Health Impact of Herbs and Nutritional Supplements, Pharm. Biol., 47, 761, 10.1080/13880200902991581
Bertilsson, 1998, Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction, Proc. Natl. Acad. Sci. USA, 95, 12208, 10.1073/pnas.95.21.12208
Blumberg, 1998, SXR, a novel steroid and xenobiotic-sensing nuclear receptor, Genes Dev., 12, 3195, 10.1101/gad.12.20.3195
Lehmann, 1998, The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions, J. Clin. Investig., 102, 1016, 10.1172/JCI3703
Moore, 2006, International Union of Pharmacology. LXII. The NR1H and NR1I receptors: Constitutive androstane receptor, pregnene X receptor, farnesoid X receptor alpha, farnesoid X receptor beta, liver X receptor alpha, liver X receptor beta, and vitamin D receptor, Pharm. Rev., 58, 742, 10.1124/pr.58.4.6
Nicolussi, 2020, Clinical relevance of St. John’s wort drug interactions revisited, Br. J. Pharmacol., 177, 1212, 10.1111/bph.14936
Huang, 2004, Meclizine is an agonist ligand for mouse constitutive androstane receptor (CAR) and an inverse agonist for human CAR, Mol. Endocrinol., 18, 2402, 10.1210/me.2004-0046
Xie, 2000, Humanized xenobiotic response in mice expressing nuclear receptor SXR, Nature, 406, 435, 10.1038/35019116
Zhang, 2002, Modulation of acetaminophen-induced hepatotoxicity by the xenobiotic receptor CAR, Science, 298, 422, 10.1126/science.1073502
Prakash, C., Zuniga, B., Song, C.S., Jiang, S., Cropper, J., Park, S., and Chatterjee, B. (2015). Nuclear Receptors in Drug Metabolism, Drug Response and Drug Interactions. Nucl. Recept. Res., 2.
Jeuken, 2003, Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits, J. Agric. Food Chem., 51, 5478, 10.1021/jf030252u
Wei, 2016, A Molecular Aspect in the Regulation of Drug Metabolism: Does PXR-Induced Enzyme Expression Always Lead to Functional Changes in Drug Metabolism?, Curr. Pharmacol. Rep., 2, 187, 10.1007/s40495-016-0062-1
Piscitelli, 2000, Indinavir concentrations and St John’s wort, Lancet, 355, 547, 10.1016/S0140-6736(99)05712-8
Ruschitzka, 2000, Acute heart transplant rejection due to Saint John’s wort, Lancet, 355, 548, 10.1016/S0140-6736(99)05467-7
Johne, 1999, Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum), Clin. Pharmacol. Ther., 66, 338, 10.1053/cp.1999.v66.a101944
Gaid, 2018, Biotechnological production of hyperforin for pharmaceutical formulation, Eur. J. Pharm. Biopharm., 126, 10, 10.1016/j.ejpb.2017.03.024
Wentworth, 2000, St John’s wort, a herbal antidepressant, activates the steroid X receptor, J. Endocrinol., 166, R11, 10.1677/joe.0.166r011
Moore, 2000, St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor, Proc. Natl. Acad. Sci. USA, 97, 7500, 10.1073/pnas.130155097
Biber, 1998, Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers, Pharmacopsychiatry, 31, 36, 10.1055/s-2007-979344
Goodwin, 2001, Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor, Mol. Pharmacol., 60, 427
Maglich, 2002, Nuclear pregnane x receptor and constitutive androstane receptor regulate overlapping but distinct sets of genes involved in xenobiotic detoxification, Mol. Pharmacol., 62, 638, 10.1124/mol.62.3.638
Pascussi, 2003, The expression of CYP2B6, CYP2C9 and CYP3A4 genes: A tangle of networks of nuclear and steroid receptors, Biochim. Biophys. Acta, 1619, 243, 10.1016/S0304-4165(02)00483-X
Geick, 2001, Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin, J. Biol. Chem., 276, 14581, 10.1074/jbc.M010173200
Kast, 2002, Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor, J. Biol. Chem., 277, 2908, 10.1074/jbc.M109326200
Durr, 2000, St John’s Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4, Clin. Pharmacol Ther., 68, 598, 10.1067/mcp.2000.112240
Hennessy, 2002, St John’s wort increases expression of P-glycoprotein: Implications for drug interactions, Br. J. Clin. Pharmacol., 53, 75, 10.1046/j.0306-5251.2001.01516.x
Mai, 2004, Hyperforin content determines the magnitude of the St John’s wort-cyclosporine drug interaction, Clin. Pharmacol. Ther., 76, 330, 10.1016/j.clpt.2004.07.004
Mueller, 2004, Effect of St John’s wort dose and preparations on the pharmacokinetics of digoxin, Clin. Pharmacol. Ther., 75, 546, 10.1016/j.clpt.2004.01.014
Mueller, 2006, The extent of induction of CYP3A by St. John’s wort varies among products and is linked to hyperforin dose, Eur. J. Clin. Pharmacol., 62, 29, 10.1007/s00228-005-0061-3
Mueller, 2009, No clinically relevant CYP3A induction after St. John’s wort with low hyperforin content in healthy volunteers, Eur. J. Clin. Pharmacol., 65, 81, 10.1007/s00228-008-0554-y
Vlachojannis, 2019, Understanding drug interactions with St John’s wort (Hypericum perforatum L.): Impact of hyperforin content, J. Pharm. Pharmacol., 71, 129
Loughren, 2020, Influence of St. John’s Wort on Intravenous Fentanyl Pharmacokinetics, Pharmacodynamics, and Clinical Effects: A Randomized Clinical Trial, Anesthesiology, 132, 491, 10.1097/ALN.0000000000003065
Wang, 2001, The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity, Clin. Pharmacol. Ther., 70, 317, 10.1016/S0009-9236(01)00127-8
Markowitz, 2003, Effect of St John’s wort on drug metabolism by induction of cytochrome P450 3A4 enzyme, JAMA, 290, 1500, 10.1001/jama.290.11.1500
Markowitz, 2000, Effect of St. John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers, Life Sci., 66, PL133-139, 10.1016/S0024-3205(99)00659-1
Sugimoto, 2001, Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin, Clin. Pharmacol. Ther., 70, 518, 10.1016/S0009-9236(01)64092-X
Johne, 2002, Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St. John’s wort (Hypericum perforatum), J. Clin. Psychopharmacol., 22, 46, 10.1097/00004714-200202000-00008
Gurley, 2002, Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans, Clin. Pharmacol. Ther., 72, 276, 10.1067/mcp.2002.126913
Gurley, 2005, Clinical assessment of effects of botanical supplementation on cytochrome P450 phenotypes in the elderly: St John’s wort, garlic oil, Panax ginseng and Ginkgo biloba, Drugs Aging, 22, 525, 10.2165/00002512-200522060-00006
Oppliger, 2003, Methadone maintenance treatment and St. John’s Wort—A case report, Pharmacopsychiatry, 36, 35, 10.1055/s-2003-38090
Hall, 2003, The interaction between St John’s wort and an oral contraceptive, Clin. Pharmacol. Ther., 74, 525, 10.1016/j.clpt.2003.08.009
Murphy, 2005, Interaction of St. John’s Wort with oral contraceptives: Effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding, Contraception, 71, 402, 10.1016/j.contraception.2004.11.004
Dresser, 2003, Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects, Clin. Pharmacol. Ther., 73, 41, 10.1067/mcp.2003.10
Jiang, 2004, Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects, Br. J. Clin. Pharmacol., 57, 592, 10.1111/j.1365-2125.2003.02051.x
Frye, 2004, Effect of St John’s wort on imatinib mesylate pharmacokinetics, Clin. Pharmacol. Ther., 76, 323, 10.1016/j.clpt.2004.06.007
Wang, 2004, St John’s wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole, Clin. Pharmacol. Ther., 75, 191, 10.1016/j.clpt.2003.09.014
Wang, 2004, The influence of St John’s Wort on CYP2C19 activity with respect to genotype, J. Clin. Pharmacol., 44, 577, 10.1177/0091270004265642
Hebert, 2004, Effects of St. John’s wort (Hypericum perforatum) on tacrolimus pharmacokinetics in healthy volunteers, J. Clin. Pharmacol., 44, 89, 10.1177/0091270003261078
Tannergren, 2004, St John’s wort decreases the bioavailability of R- and S-verapamil through induction of the first-pass metabolism, Clin. Pharmacol. Ther., 75, 298, 10.1016/j.clpt.2003.12.012
Rengelshausen, 2005, Opposite effects of short-term and long-term St John’s wort intake on voriconazole pharmacokinetics, Clin. Pharmacol. Ther., 78, 25, 10.1016/j.clpt.2005.01.024
Schwarz, 2007, Induction of intestinal P-glycoprotein by St John’s wort reduces the oral bioavailability of talinolol, Clin. Pharmacol. Ther., 81, 669, 10.1038/sj.clpt.6100191
Xu, 2008, Effects of St John’s wort and CYP2C9 genotype on the pharmacokinetics and pharmacodynamics of gliclazide, Br. J. Pharmacol., 153, 1579, 10.1038/sj.bjp.0707685
Wang, 2009, Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John’s wort-induced activity of cytochrome P450 3A4 enzyme, Br. J. Clin. Pharmacol., 67, 255, 10.1111/j.1365-2125.2008.03344.x
Peltoniemi, 2012, St John’s wort greatly decreases the plasma concentrations of oral S-ketamine, Fundam. Clin. Pharmacol., 26, 743, 10.1111/j.1472-8206.2011.00954.x
Hojo, 2011, Drug interaction between St John’s wort and zolpidem in healthy subjects, J. Clin. Pharmacol. Ther., 36, 711, 10.1111/j.1365-2710.2010.01223.x
Markert, 2014, Influence of St. John’s wort on the steady-state pharmacokinetics and metabolism of bosentan, Int. J. Clin. Pharmcol. Ther., 52, 328, 10.5414/CP202048
Markert, 2015, The effect of induction of CYP3A4 by St John’s wort on ambrisentan plasma pharmacokinetics in volunteers of known CYP2C19 genotype, Basic Clin. Pharmacol. Toxicol., 116, 423, 10.1111/bcpt.12332
Goey, 2014, The effect of St John’s wort on the pharmacokinetics of docetaxel, Clin. Pharmcokinet., 53, 103, 10.1007/s40262-013-0102-5
Gordon, 2009, Reduced efficacy of rosuvastatin by St. John’s Wort, Am. J. Med., 122, e1, 10.1016/j.amjmed.2008.09.033
Martin, 2003, Metabolism, excretion, and pharmacokinetics of rosuvastatin in healthy adult male volunteers, Clin. Pharmacol. Ther., 25, 2822
Keskitalo, 2009, ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin, Clin. Pharmacol. Ther., 86, 197, 10.1038/clpt.2009.79
Stage, 2015, Intake of St John’s wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone, Br. J. Clin. Pharmacol., 79, 298, 10.1111/bcp.12510
Pentikainen, 1979, Pharmacokinetics of metformin after intravenous and oral administration to man, Eur. J. Clin. Pharmacol., 16, 195, 10.1007/BF00562061
Chen, 2010, Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin, Pharmacogenet. Genom., 20, 687, 10.1097/FPC.0b013e32833fe789
Nies, 2009, Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver, Hepatology, 50, 1227, 10.1002/hep.23103
Fan, 2011, The pregnane X receptor agonist St John’s Wort has no effects on the pharmacokinetics and pharmacodynamics of repaglinide, Clin. Pharmacokinet., 50, 605, 10.2165/11587310-000000000-00000
Niemi, 2005, Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics, Clin. Pharmacol. Ther., 77, 468, 10.1016/j.clpt.2005.01.018
Cho, 2011, Rifampin enhances the glucose-lowering effect of metformin and increases OCT1 mRNA levels in healthy participants, Clin. Pharmacol. Ther., 89, 416, 10.1038/clpt.2010.266
Niemi, 2000, Rifampin decreases the plasma concentrations and effects of repaglinide, Clin. Pharmacol. Ther., 68, 495, 10.1067/mcp.2000.111183
Bogers, 2012, Interaction of St John’s wort (Hypericum perforatum) with clozapine, Int. Clin. Psychopharmacol., 27, 121, 10.1097/YIC.0b013e32834e8afd
Yeung, 2008, Identification of Ginkgo biloba as a novel activator of pregnane X receptor, Drug Metab. Dispos., 36, 2270, 10.1124/dmd.108.023499
Li, 2009, Bioactive terpenoids and flavonoids from Ginkgo biloba extract induce the expression of hepatic drug-metabolizing enzymes through pregnane X receptor, constitutive androstane receptor, and aryl hydrocarbon receptor-mediated pathways, Pharm. Res., 26, 872, 10.1007/s11095-008-9788-8
Lau, 2012, Selective agonism of human pregnane X receptor by individual ginkgolides, Drug Metab. Dispos., 40, 1113, 10.1124/dmd.112.045013
Gaudineau, 2004, Inhibition of human P450 enzymes by multiple constituents of the Ginkgo biloba extract, Biochem. Biophys. Res. Commun., 318, 1072, 10.1016/j.bbrc.2004.04.139
Taki, 2011, Effects of Ginkgo biloba extract on the pharmacokinetics and pharmacodynamics of tolbutamide in protein-restricted rats, J. Pharm. Pharmacol., 63, 1238, 10.1111/j.2042-7158.2011.01327.x
Hussain, 2015, Effects of Gingko biloba extract on tissue distribution of fluoxetine and venlafaxine in rats, J. Intercult. Ethnopharmacol., 4, 234, 10.5455/jice.20150628102732
Markowitz, 2003, Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers, J. Clin. Psychopharmacol., 23, 576, 10.1097/01.jcp.0000095340.32154.c6
Robertson, 2008, Effect of Ginkgo biloba extract on lopinavir, midazolam and fexofenadine pharmacokinetics in healthy subjects, Curr. Med. Res. Opin., 24, 591, 10.1185/030079908X260871
Penzak, 2008, Limitations of using a single postdose midazolam concentration to predict CYP3A-mediated drug interactions, J. Clin. Pharmacol., 48, 671, 10.1177/0091270008317305
Uchida, 2006, Effects of Ginkgo biloba extract on pharmacokinetics and pharmacodynamics of tolbutamide and midazolam in healthy volunteers, J. Clin. Pharmacol., 46, 1290, 10.1177/0091270006292628
Yoshioka, 2004, Studies on interactions between functional foods or dietary supplements and medicines. IV. Effects of Ginkgo biloba leaf extract on the pharmacokinetics and pharmacodynamics of nifedipine in healthy volunteers, Biol. Pharm. Bull., 27, 2006, 10.1248/bpb.27.2006
Greenblatt, 2006, Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: In vitro and clinical studies, Clin. Pharmacol. Ther., 79, 125, 10.1016/j.clpt.2005.09.014
Jiang, 2005, Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects, Br. J. Clin. Pharmacol., 59, 425, 10.1111/j.1365-2125.2005.02322.x
Hellum, 2009, Trade herbal products and induction of CYP2C19 and CYP2E1 in cultured human hepatocytes, Basic Clin. Pharmacol. Toxicol., 105, 58, 10.1111/j.1742-7843.2009.00412.x
Yin, 2004, Pharmacogenetics and herb-drug interactions: Experience with Ginkgo biloba and omeprazole, Pharmacogenetics, 14, 841, 10.1097/00008571-200412000-00007
Lei, 2009, Lack of effect of Ginkgo biloba on voriconazole pharmacokinetics in Chinese volunteers identified as CYP2C19 poor and extensive metabolizers, Ann. Pharmacother., 43, 726, 10.1345/aph.1L537
Zuo, 2010, Effects of Ginkgo biloba extracts on diazepam metabolism: A pharmacokinetic study in healthy Chinese male subjects, Eur. J. Clin. Pharmacol., 66, 503, 10.1007/s00228-010-0795-4
Wiegman, 2009, Interaction of Ginkgo biloba with efavirenz, AIDS, 23, 1184, 10.1097/QAD.0b013e32832c412b
Lei, 2009, Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers, Br. J. Clin. Pharmacol., 68, 201, 10.1111/j.1365-2125.2009.03442.x
Mauro, 2003, Impact of Ginkgo biloba on the pharmacokinetics of digoxin, Am. J. Ther., 10, 247, 10.1097/00045391-200307000-00003
Fan, 2009, Effects of Ginkgo biloba extract ingestion on the pharmacokinetics of talinolol in healthy Chinese volunteers, Ann. Pharmacother., 43, 944, 10.1345/aph.1L656
Ofer, 2005, Modulation of drug transport by selected flavonoids: Involvement of P-gp and OCT?, Eur. J. Pharm. Sci., 25, 263, 10.1016/j.ejps.2005.03.001
Blonk, 2012, Effect of Ginkgo biloba on the pharmacokinetics of raltegravir in healthy volunteers, Antimicrob. Agents Chemother., 56, 5070, 10.1128/AAC.00672-12
Moss, 2011, Raltegravir is a substrate for SLC22A6: A putative mechanism for the interaction between raltegravir and tenofovir, Antimicrob. Agents Chemother., 55, 879, 10.1128/AAC.00623-10
Zhou, 2014, Evaluation of in vitro inhibition and induction of cytochrome P450 activities by hydrolyzed ginkgolides, J. Ethnopharmacol., 158, 132, 10.1016/j.jep.2014.10.023
Zadoyan, 2012, Effect of Ginkgo biloba special extract EGb 761(R) on human cytochrome P450 activity: A cocktail interaction study in healthy volunteers, Eur. J. Clin. Pharmacol., 68, 553, 10.1007/s00228-011-1174-5
Kim, 2014, The effect of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of cilostazol and its active metabolites in healthy Korean subjects, Br. J. Clin. Pharmacol., 77, 821, 10.1111/bcp.12236
Guo, 2012, Effects of Ginkgo biloba extracts on pharmacokinetics and efficacy of atorvastatin based on plasma indices, Xenobiotica, 42, 784, 10.3109/00498254.2012.661100
Lennernas, 2003, Clinical pharmacokinetics of atorvastatin, Clin. Pharmacokinet., 42, 1141, 10.2165/00003088-200342130-00005
Dai, 2013, Assessment of a pharmacokinetic and pharmacodynamic interaction between simvastatin and Ginkgo biloba extracts in healthy subjects, Xenobiotica, 43, 862, 10.3109/00498254.2013.773385
Pasanen, 2006, SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid, Pharmacogenet. Genom., 16, 873, 10.1097/01.fpc.0000230416.82349.90
Kivisto, 2007, Influence of drug transporter polymorphisms on pravastatin pharmacokinetics in humans, Pharm. Res., 24, 239, 10.1007/s11095-006-9159-2
Giardi, M.T., Rea, G., and Berra, B. (2010). Bio-farms for nutraceuticals—Functional food and safety control by biosensors. Advances in Experimental Medicine and Biology, Springer.
Foster, 2001, An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic, J. Pharm. Pharmacol. Sci., 4, 176
Greenblatt, 2006, In vitro interactions of water-soluble garlic components with human cytochromes p450, J. Nutr., 136, 806S, 10.1093/jn/136.3.806S
Yang, 2001, Mechanisms of inhibition of chemical toxicity and carcinogenesis by diallyl sulfide (DAS) and related compounds from garlic, J. Nutr., 131, 1041S, 10.1093/jn/131.3.1041S
Guyonnet, 2002, Mechanisms of protection against aflatoxin B (1) genotoxicity in rats treated by organosulfur compounds from garlic, Carcinogenesis, 23, 1335, 10.1093/carcin/23.8.1335
Zhang, 2006, Different activation patterns of rat xenobiotic metabolism genes by two constituents of garlic, Carcinogenesis, 27, 2090, 10.1093/carcin/bgl064
Berginc, 2010, In vitro interactions between aged garlic extract and drugs used for the treatment of cardiovascular and diabetic patients, Eur. J. Nutr., 49, 373, 10.1007/s00394-010-0095-x
Asdaq, 2011, The potential benefits of a garlic and hydrochlorothiazide combination as antihypertensive and cardioprotective in rats, J. Nat. Med., 65, 81, 10.1007/s11418-010-0467-9
Wang, 2011, Effect of diallyl trisulfide on the pharmacokinetics of dipyridamole in rats, Arch. Pharm. Res., 34, 1957, 10.1007/s12272-011-1116-x
Nabekura, 2005, Effects of dietary chemopreventive phytochemicals on P-glycoprotein function, Biochem. Biophys. Res. Commun., 327, 866, 10.1016/j.bbrc.2004.12.081
Markowitz, 2003, Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers, Clin. Pharmacol. Ther., 74, 170, 10.1016/S0009-9236(03)00148-6
Piscitelli, 2002, The effect of garlic supplements on the pharmacokinetics of saquinavir, Clin. Infect. Dis., 34, 234, 10.1086/324351
Berginc, 2012, The effect of garlic supplements and phytochemicals on the ADMET properties of drugs, Expert Opin. Drug Metab. Toxicol., 8, 295, 10.1517/17425255.2012.659662
Gallicano, 2003, Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers, Br. J. Clin. Pharmacol., 55, 199, 10.1046/j.1365-2125.2003.01736.x
Cox, 2006, Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel, Clin. Cancer Res., 12, 4636, 10.1158/1078-0432.CCR-06-0388
Chatterjee, 2003, Human cytochrome p450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components, Drug Metab. Dispos., 31, 1391, 10.1124/dmd.31.11.1391
Etheridge, 2007, An in vitro evaluation of cytochrome P450 inhibition and P-glycoprotein interaction with goldenseal, Ginkgo biloba, grape seed, milk thistle, and ginseng extracts and their constituents, Planta Med., 73, 731, 10.1055/s-2007-981550
Raner, 2007, Effects of herbal products and their constituents on human cytochrome P450(2E1) activity, Food Chem. Toxicol., 45, 2359, 10.1016/j.fct.2007.06.012
Sevior, 2010, Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail, Xenobiotica, 40, 245, 10.3109/00498251003592683
Sandhu, 2003, Influence of goldenseal root on the pharmacokinetics of indinavir, J. Clin. Pharmacol., 43, 1283, 10.1177/0091270003258660
Yeh, 1999, Simultaneous investigation of indinavir nonlinear pharmacokinetics and bioavailability in healthy volunteers using stable isotope labeling technique: Study design and model-independent data analysis, J. Pharm. Sci., 88, 568, 10.1021/js9802392
Gurley, 2005, In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes, Clin Pharmacol. Ther., 77, 415, 10.1016/j.clpt.2005.01.009
Gurley, 2008, Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo, Clin Pharmacol. Ther., 83, 61, 10.1038/sj.clpt.6100222
Wang, 2015, An ex vivo approach to botanical-drug interactions: A proof of concept study, J. Ethnopharmacol., 163, 149, 10.1016/j.jep.2015.01.021
Gurley, 2007, Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans, Drug Metab. Dispos., 35, 240, 10.1124/dmd.106.012708
Mathews, 2002, Inhibition of human cytochrome P450 activities by kava extract and kavalactones, Drug Metab. Dispos., 30, 1153, 10.1124/dmd.30.11.1153
Zou, 2004, Effects of kava (Kava-kava, ‘Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes, Phytomedicine, 11, 285, 10.1078/0944711041495263
Gurley, 2008, Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John’s wort, and Echinacea, Mol. Nutr. Food Res., 52, 755, 10.1002/mnfr.200600300
Budzinski, 2000, An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures, Phytomedicine, 7, 273, 10.1016/S0944-7113(00)80044-6
Yale, 2005, Analysis of the inhibitory potential of Ginkgo biloba, Echinacea purpurea, and Serenoa repens on the metabolic activity of cytochrome P450 3A4, 2D6, and 2C9, J. Altern. Complement. Med., 11, 433, 10.1089/acm.2005.11.433
Modarai, 2011, Safety of Herbal Medicinal Products: Echinacea and Selected Alkylamides Do Not Induce CYP3A4 mRNA Expression, Evid. Based Complement. Altern. Med., 2011, 213021, 10.1093/ecam/nep174
Mrozikiewicz, 2010, The effect of standardized Echinacea purpurea extract on rat cytochrome P450 expression level, Phytomedicine, 17, 830, 10.1016/j.phymed.2010.02.007
Albassam, 2015, Inhibitory effect of six herbal extracts on CYP2C8 enzyme activity in human liver microsomes, Xenobiotica, 45, 406, 10.3109/00498254.2014.989935
Gorski, 2004, The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo, Clin Pharmacol. Ther., 75, 89, 10.1016/j.clpt.2003.09.013
Gurley, 2004, In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto, Clin Pharmacol. Ther., 76, 428, 10.1016/j.clpt.2004.07.007
Abdul, 2010, Pharmacokinetic and pharmacodynamic interactions of echinacea and policosanol with warfarin in healthy subjects, Br. J. Clin. Pharmacol., 69, 508, 10.1111/j.1365-2125.2010.03620.x
Penzak, 2010, Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects, Pharmacotherapy, 30, 797, 10.1592/phco.30.8.797
Goey, 2013, Relevance of in vitro and clinical data for predicting CYP3A4-mediated herb-drug interactions in cancer patients, Cancer Treat. Rev., 39, 773, 10.1016/j.ctrv.2012.12.008
Molto, 2012, Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients, Antimicrob. Agents Chemother., 56, 5328, 10.1128/AAC.01205-12
Molto, 2011, Herb-drug interaction between Echinacea purpurea and darunavir-ritonavir in HIV-infected patients, Antimicrob. Agents Chemother., 55, 326, 10.1128/AAC.01082-10
Awortwe, 2015, Echinacea purpurea up-regulates CYP1A2, CYP3A4 and MDR1 gene expression by activation of pregnane X receptor pathway, Xenobiotica, 45, 218, 10.3109/00498254.2014.973930
Awortwe, 2018, MicroRNA-655-3p regulates Echinacea purpurea mediated activation of ABCG2, Xenobiotica, 48, 1050, 10.1080/00498254.2017.1390624
Sridar, 2004, Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases, Drug Metab. Dispos., 32, 587, 10.1124/dmd.32.6.587
Brantley, 2010, Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations, J. Pharmacol. Exp. Ther., 332, 1081, 10.1124/jpet.109.161927
Mooiman, 2013, Milk thistle’s active components silybin and isosilybin: Novel inhibitors of PXR-mediated CYP3A4 induction, Drug Metab. Dispos., 41, 1494, 10.1124/dmd.113.050971
Gufford, 2015, Milk Thistle Constituents Inhibit Raloxifene Intestinal Glucuronidation: A Potential Clinically Relevant Natural Product-Drug Interaction, Drug Metab. Dispos., 43, 1353, 10.1124/dmd.115.065086
Zhang, 2003, Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport, J. Pharmacol. Exp. Ther., 304, 1258, 10.1124/jpet.102.044412
Zhang, 2003, Effect of the flavonoids biochanin A and silymarin on the P-glycoprotein-mediated transport of digoxin and vinblastine in human intestinal Caco-2 cells, Pharm. Res., 20, 1184, 10.1023/A:1025044913766
Piscitelli, 2002, Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers, Pharmacotherapy, 22, 551, 10.1592/phco.22.8.551.33205
DiCenzo, 2003, Coadministration of milk thistle and indinavir in healthy subjects, Pharmacotherapy, 23, 866, 10.1592/phco.23.7.866.32723
Rajnarayana, 2004, Study on the influence of silymarin pretreatment on metabolism and disposition of metronidazole, Arzneimittelforschung, 54, 109
Raucy, 2003, Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products, Drug Metab. Dispos., 31, 533, 10.1124/dmd.31.5.533
Gurley, 2006, Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: Comparison of a milk thistle and black cohosh product to rifampin and clarithromycin, J. Clin. Pharmacol., 46, 201, 10.1177/0091270005284854
Baker, 2005, Effect of milk thistle (Silybum marianum) on the pharmacokinetics of irinotecan, Clin. Cancer Res., 11, 7800, 10.1158/1078-0432.CCR-05-1288
Molto, 2012, Effect of milk thistle on the pharmacokinetics of darunavir-ritonavir in HIV-infected patients, Antimicrob. Agents Chemother., 56, 2837, 10.1128/AAC.00025-12
Frye, 2014, The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity, Drug Metab. Dispos., 42, 1611, 10.1124/dmd.114.057232
Brantley, 2013, A systematic approach to evaluate herb-drug interaction mechanisms: Investigation of milk thistle extracts and eight isolated constituents as CYP3A inhibitors, Drug Metab. Dispos., 41, 1662, 10.1124/dmd.113.052563
Wang, 2014, Inhibitory effect of silybin on pharmacokinetics of imatinib in vivo and in vitro, Can. J. Physiol. Pharmacol., 92, 961, 10.1139/cjpp-2014-0260
Han, 2009, Effect of silymarin on the pharmacokinetics of losartan and its active metabolite E-3174 in healthy Chinese volunteers, Eur. J. Clin. Pharmacol., 65, 585, 10.1007/s00228-009-0624-9
Gurley, 2006, Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans, Drug Metab. Dispos., 34, 69, 10.1124/dmd.105.006312
Han, 2009, Effect of continuous silymarin administration on oral talinolol pharmacokinetics in healthy volunteers, Xenobiotica, 39, 694, 10.1080/00498250903060077
Flaig, 2007, A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients, Investig. New Drugs, 25, 139, 10.1007/s10637-006-9019-2
Scuteri, 2018, Antinociceptive effect of inhalation of the essential oil of bergamot in mice, Fitoterapia, 129, 20, 10.1016/j.fitote.2018.06.007
Scuteri, 2017, Aromatherapy and Aromatic Plants for the Treatment of Behavioural and Psychological Symptoms of Dementia in Patients with Alzheimer’s Disease: Clinical Evidence and Possible Mechanisms, Evid. Based Complement. Altern. Med., 2017, 9416305, 10.1155/2017/9416305
Scuteri, D., Rombola, L., Morrone, L.A., Bagetta, G., Sakurada, S., Sakurada, T., Tonin, P., and Corasaniti, M.T. (2019). Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach. Int. J. Mol. Sci., 20.
Scuteri, 2019, Neuropharmacological Properties of the Essential Oil of Bergamot for the Clinical Management of Pain-Related BPSDs, Curr. Med. Chem., 26, 3764, 10.2174/0929867325666180307115546
Obach, 2000, Inhibition of human cytochrome P450 enzymes by constituents of St. John’s Wort, an herbal preparation used in the treatment of depression, J. Pharmacol. Exp. Ther., 294, 88
Folashade, 2012, Standardization of herbal medicines—A review, Int. J. Biodivers. Conserv., 4, 101